Drug Profile
Encenicline - Bayer
Alternative Names: Alpha-7 nAChR; EVP-6124; MT-4666Latest Information Update: 03 Sep 2021
Price :
$50
*
At a glance
- Originator Bayer HealthCare
- Developer Bayer HealthCare; FORUM Pharmaceuticals; Mitsubishi Tanabe Pharma Corporation
- Class 2 ring heterocyclic compounds; Amides; Azabicyclo compounds; Nootropics; Quinuclidines; Thiophenes
- Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Cognition disorders
Most Recent Events
- 03 Sep 2021 Discontinued - Phase-I for Cognition disorders in Hungary, Slovakia, Czech Republic (PO)
- 03 Sep 2021 Discontinued - Phase-II for Alzheimer's disease in USA, Russia, Romania, Serbia, Ukraine (PO)
- 03 Sep 2021 Discontinued - Phase-II for Cognition disorders in Russia, Ukraine, Serbia (PO)